retinal vein occlusion

Summary

Summary: Occlusion of the retinal vein. Those at high risk for this condition include patients with hypertension, diabetes mellitus, arteriosclerosis, and other cardiovascular diseases.

Top Publications

  1. doi Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study
    David Boyer
    Retina Vitreous Associates Medical Group, Los Angeles, CA, USA
    Ophthalmology 119:1024-32. 2012
  2. pmc A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlu
    Ingrid U Scott
    EMMES Corporation, Rockville, MD 20850, USA
    Arch Ophthalmol 127:1115-28. 2009
  3. doi Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion
    Julia A Haller
    Wills Eye Institute, Philadelphia, Pennsylvania 19107, USA
    Ophthalmology 117:1134-1146.e3. 2010
  4. doi Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study
    Peter A Campochiaro
    Departments of Ophthalmology and Neuroscience, The Johns Hopkins School of Medicine, Baltimore, MD 21287 9277, USA
    Ophthalmology 118:2041-9. 2011
  5. doi Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results
    Julia A Haller
    Wills Eye Institute, Philadelphia, Pennsylvania 19107, USA
    Ophthalmology 118:2453-60. 2011
  6. doi Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double-masked clinical study
    David L J Epstein
    Department of Ophthalmology, Karolinska Institutet, St Eriks Eye Hospital, Stockholm, Sweden
    Ophthalmology 119:1184-9. 2012
  7. pmc A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlus
    Michael S Ip
    EMMES Corporation, Rockville, MD 20850, USA
    Arch Ophthalmol 127:1101-14. 2009
  8. doi Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study
    David M Brown
    Retinal Consultants of Houston, Houston, Texas, USA
    Ophthalmology 118:1594-602. 2011
  9. doi Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial
    Jeffrey S Heier
    Ophthalmic Consultants of Boston, Boston, Massachusetts, USA
    Ophthalmology 119:802-9. 2012
  10. doi Comparison of cytokine levels from undiluted vitreous of untreated patients with retinal vein occlusion
    Michael J Koss
    Department of Ophthalmology, Section of Vitreo Retinal Surgery, Goethe University, 60590 Frankfurt am Main, Germany
    Acta Ophthalmol 90:e98-e103. 2012

Detail Information

Publications253 found, 100 shown here

  1. doi Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study
    David Boyer
    Retina Vitreous Associates Medical Group, Los Angeles, CA, USA
    Ophthalmology 119:1024-32. 2012
    To assess the efficacy and safety of intravitreal vascular endothelial growth factor (VEGF) Trap-Eye in eyes with macular edema secondary to central retinal vein occlusion (CRVO).
  2. pmc A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlu
    Ingrid U Scott
    EMMES Corporation, Rockville, MD 20850, USA
    Arch Ophthalmol 127:1115-28. 2009
    ..without dense macular hemorrhage and deferral of photocoagulation until hemorrhage clears in eyes with dense macular hemorrhage) for eyes with vision loss associated with macular edema secondary to branch retinal vein occlusion (BRVO).
  3. doi Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion
    Julia A Haller
    Wills Eye Institute, Philadelphia, Pennsylvania 19107, USA
    Ophthalmology 117:1134-1146.e3. 2010
    ..Irvine, CA) compared with sham in eyes with vision loss due to macular edema (ME) associated with branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO).
  4. doi Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study
    Peter A Campochiaro
    Departments of Ophthalmology and Neuroscience, The Johns Hopkins School of Medicine, Baltimore, MD 21287 9277, USA
    Ophthalmology 118:2041-9. 2011
    Assess the 12-month efficacy and safety of intraocular injections of 0.3 mg or 0.5 mg ranibizumab in patients with macular edema after central retinal vein occlusion (CRVO).
  5. doi Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results
    Julia A Haller
    Wills Eye Institute, Philadelphia, Pennsylvania 19107, USA
    Ophthalmology 118:2453-60. 2011
    To evaluate the safety and efficacy of 1 or 2 treatments with dexamethasone intravitreal implant (DEX implant) over 12 months in eyes with macular edema owing to branch or central retinal vein occlusion (BRVO or CRVO).
  6. doi Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double-masked clinical study
    David L J Epstein
    Department of Ophthalmology, Karolinska Institutet, St Eriks Eye Hospital, Stockholm, Sweden
    Ophthalmology 119:1184-9. 2012
    To evaluate the efficacy of intraocular injections with bevacizumab in patients with macular edema (ME) secondary to central retinal vein occlusion (CRVO).
  7. pmc A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlus
    Michael S Ip
    EMMES Corporation, Rockville, MD 20850, USA
    Arch Ophthalmol 127:1101-14. 2009
    To compare the efficacy and safety of 1-mg and 4-mg doses of preservative-free intravitreal triamcinolone with observation for eyes with vision loss associated with macular edema secondary to perfused central retinal vein occlusion (CRVO).
  8. doi Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study
    David M Brown
    Retinal Consultants of Houston, Houston, Texas, USA
    Ophthalmology 118:1594-602. 2011
    Assess 12-month efficacy and safety of intraocular injections of 0.3 mg or 0.5 mg ranibizumab in patients with macular edema after branch retinal vein occlusion (BRVO).
  9. doi Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial
    Jeffrey S Heier
    Ophthalmic Consultants of Boston, Boston, Massachusetts, USA
    Ophthalmology 119:802-9. 2012
    To assess long-term safety and efficacy of intraocular ranibizumab injections in patients with macular edema after retinal vein occlusion (RVO).
  10. doi Comparison of cytokine levels from undiluted vitreous of untreated patients with retinal vein occlusion
    Michael J Koss
    Department of Ophthalmology, Section of Vitreo Retinal Surgery, Goethe University, 60590 Frankfurt am Main, Germany
    Acta Ophthalmol 90:e98-e103. 2012
    To compare cytokines in undiluted vitreous of treatment-naïve patients with macular oedema without vitreomacular traction secondary to branch (BRVO), central (CRVO) and hemi-central (H-CRVO) retinal vein occlusion.
  11. doi VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study
    Frank G Holz
    Department of Ophthalmology, University of Bonn, Ernst Abbe Street 2, Bonn 53127, Germany
    Br J Ophthalmol 97:278-84. 2013
    To evaluate intravitreal VEGF Trap-Eye (VTE) in patients with macular oedema secondary to central retinal vein occlusion (CRVO).
  12. doi Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab
    Marion Funk
    Department of Ophthalmology, Medical University of Vienna, Vienna, Austria
    Invest Ophthalmol Vis Sci 50:1025-32. 2009
    To investigate concentrations of growth factors and inflammatory cytokines in eyes with central (CRVO) and branch (BRVO) retinal vein occlusion before and during therapy with bevacizumab and to identify associations with disease activity.
  13. pmc The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia
    Sophie Rogers
    Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, Vic, Australia
    Ophthalmology 117:313-9.e1. 2010
    To summarize the prevalence of retinal vein occlusion (RVO) from studies in the United States, Europe, Asia, and Australia.
  14. pmc SCORE Study report #11: incidences of neovascular events in eyes with retinal vein occlusion
    Clement K Chan
    Southern California Desert Retina Consultants, Palm Springs, CA, USA
    Ophthalmology 118:1364-72. 2011
    To investigate in The Standard Care versus COrticosteroid for REtinal Vein Occlusion (SCORE) Study: (1) incidences of neovascular events and retinal capillary nonperfusion (abbreviated as "nonperfusion"), and their relationship with ..
  15. doi Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study
    David M Brown
    Retina Consultants of Houston, The Methodist Hospital, Houston, TX, USA
    Am J Ophthalmol 155:429-437.e7. 2013
    To evaluate intravitreal aflibercept injections (IAI; also called VEGF Trap-Eye) for patients with macular edema secondary to central retinal vein occlusion (CRVO).
  16. doi Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion
    Xiaoyan Ding
    State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat Sen University, Guangzhou, China
    Retina 31:838-45. 2011
    To compare the efficacy and safety of intravitreal triamcinolone acetonide (IVT) versus intravitreal bevacizumab (IVB) for the treatment of macular edema (ME) secondary to central retinal vein occlusion.
  17. doi Combination therapy in diabetic macular oedema and retinal vein occlusion--past and present
    Michael J Koss
    Department of Ophthalmology, Goethe University, Frankfurt Main, Germany
    Acta Ophthalmol 90:580-9. 2012
    ..therapies in the intravitreal medical treatment of diabetic macular oedema or macular oedema, secondary to retinal vein occlusion. Since the introduction of anti-inflammatory or anti-VEGF drugs combined with or used alternatively to ..
  18. doi Comparison of aqueous concentrations of angiogenic and inflammatory cytokines in diabetic macular oedema and macular oedema due to branch retinal vein occlusion
    Won June Lee
    Department of Ophthalmology, Hanyang University College of Medicine, Seoul, Republic of Korea
    Br J Ophthalmol 96:1426-30. 2012
    ..in the development and progression of diabetic macular oedema (DMO) and macular oedema (MO) due to branch retinal vein occlusion (BRVO-MO)...
  19. doi Bevacizumab compared with macular laser grid photocoagulation for cystoid macular edema in branch retinal vein occlusion
    Vincenzo Russo
    Department of Ophthalmology, Policlinico di Foggia, University of Foggia, Foggia, Italy
    Retina 29:511-5. 2009
    To evaluate the outcome of cystoid macular edema treated with intravitreal injections of bevacizumab and macular grid laser photocoagulation (GLP), in patients with perfused branch retinal vein occlusion.
  20. doi Expression profiles of cytokines and chemokines in vitreous fluid in diabetic retinopathy and central retinal vein occlusion
    Yukihiko Suzuki
    Department of Ophthalmology, Hirosaki University Graduate School of Medicine, 5 Zaifu, Hirosaki, Aomori, 036 8562, Japan
    Jpn J Ophthalmol 55:256-63. 2011
    ..in vitreous fluid is important in the development and progression of diabetic retinopathy (DR) and central retinal vein occlusion (CRVO)...
  21. doi Prevalence and risk factors of retinal vein occlusion in an Asian population
    L L Lim
    Centre for Eye Research Australia, University of Melbourne, Australia
    Br J Ophthalmol 92:1316-9. 2008
    To describe the prevalence and risk factors of retinal vein occlusion (RVO) in an Asian population.
  22. doi Functional-morphologic correlates in patients with branch retinal vein occlusion and macular edema
    Hidetaka Noma
    Department of Ophthalmology, Yachiyo Medical Center, Tokyo Women s Medical University, Owada shinden, Yachiyo, Chiba, Japan
    Retina 31:2102-8. 2011
    To investigate the relations among best-corrected visual acuity, retinal sensitivity, retinal thickness, and retinal volume in patients with branch retinal vein occlusion, and macular edema.
  23. doi Aqueous vascular endothelial growth factor levels are associated with serous macular detachment secondary to branch retinal vein occlusion
    Sung Pyo Park
    Department of Ophthalmology, Hallym University Medical School, Seoul, Korea
    Retina 30:281-6. 2010
    ..to determine whether aqueous levels of vascular endothelial growth factor (VEGF) and pigment epithelium-derived factor (PEDF) are associated with developments of serous retinal detachment (SRD) secondary to branch retinal vein occlusion.
  24. ncbi Foveal photoreceptor layer in eyes with persistent cystoid macular edema associated with branch retinal vein occlusion
    Masafumi Ota
    Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Sakyo ku, Kyoto, Japan
    Am J Ophthalmol 145:273-280. 2008
    To study the correlation of visual acuity and the foveal photoreceptor layer in eyes with persistent cystoid macular edema associated with branch retinal vein occlusion (BRVO).
  25. ncbi Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion
    H Noma
    Department of Ophthalmology and Visual Science, Graduate School of Biomedical Sciences, Hiroshima University, Minami Ku, Hiroshima, Japan
    Eye (Lond) 22:42-8. 2008
    ..whether the aqueous levels of vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6) are correlated to the vitreous levels of these substances and to the severity of macular oedema in branch retinal vein occlusion (BRVO).
  26. doi Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial
    F Prager
    Department of Ophthalmology, Medical University of Vienna, Waehringer Guertel 18 20, 1190 Wien, Austria
    Br J Ophthalmol 93:452-6. 2009
    ..aim of the study was to evaluate functional and anatomical changes after intravitreal bevacizumab (Avastin) in eyes with persistent macular oedema secondary to branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO).
  27. ncbi Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6
    Hidetaka Noma
    Department of Ophthalmology and Visual Science, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan
    Am J Ophthalmol 140:256-61. 2005
    To determine whether correlations between vascular endothelial growth factor (VEGF) or interleukin-6 (IL-6) contribute to the pathogenesis of macular edema in eyes of patients with branch retinal vein occlusion (BRVO).
  28. ncbi Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study
    Sudha Cugati
    Centre for Vision Research, Department of Ophthalmology, University of Sydney, Westmead Hospital, Hawkesbury Road, Westmead, NSW 2145, Australia
    Arch Ophthalmol 124:726-32. 2006
    To assess the 10-year incidence of retinal vein occlusion (RVO) and its predictors in an older population.
  29. doi Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study
    K Kriechbaum
    University Eye Hospital Zurich, Frauenklinikstrasse 24, CH 8091 Zurich, Switzerland
    Br J Ophthalmol 92:518-22. 2008
    To evaluate efficacy and safety of intravitreal bevacizumab (Avastin) in eyes with macular oedema secondary to central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO).
  30. doi The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study
    Ronald Klein
    Department of Ophthalmology and Visual Sciences, University of Wisconsin School of Medicine and Public Health, Madison, WI 53726 2336, USA
    Arch Ophthalmol 126:513-8. 2008
    To describe the 15-year incidence of retinal vein occlusion (central retinal vein occlusion and branch retinal vein occlusion) and associated risk factors.
  31. ncbi Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion
    Hidetaka Noma
    Department of Ophthalmology and Visual Science, Graduate School of Biomedical Sciences, Hiroshima University, 1 2 3, Kasumi cho, Minami Ku, Hiroshima, 734 8551, Japan
    Graefes Arch Clin Exp Ophthalmol 244:309-15. 2006
    ..whether vascular endothelial growth factor (VEGF) or interleukin-6 (IL-6) contributes to the pathogenesis of macular edema in eyes with branch retinal vein occlusion (BRVO), the correlations between these factors were investigated.
  32. pmc Traditional and novel cardiovascular risk factors for retinal vein occlusion: the multiethnic study of atherosclerosis
    Ning Cheung
    Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, University of Melbourne, East Melbourne, Victoria, Australia
    Invest Ophthalmol Vis Sci 49:4297-302. 2008
    To describe the prevalence of retinal vein occlusion (RVO) and its association with cardiovascular, inflammatory, and hematologic risk factors in a multiethnic cohort.
  33. doi Homocysteine, methylenetetrahydrofolate reductase C677T polymorphism, and risk of retinal vein occlusion: a meta-analysis
    Stuart J McGimpsey
    Directorate of Ophthalmology, The Royal Victoria Hospital, The Belfast Health and Social Care Trust, Grosvenor Road, Belfast, Ireland
    Ophthalmology 116:1778-1787.e1. 2009
    ..To assess the role of plasma total homocysteine (tHcy) concentrations and homozygosity for the thermolabile variant of the methylenetetrahydrofolate reductase (MTHFR) C677T gene as risk factors for retinal vascular occlusive disease...
  34. doi Association of retinal sensitivity and morphology during antiangiogenic treatment of retinal vein occlusion over one year
    Katharina Kriechbaum
    Department of Ophthalmology, Medical University of Vienna, Vienna, Austria
    Ophthalmology 116:2415-21. 2009
    ..endothelial growth factor (VEGF) therapy with bevacizumab (Avastin) in patients with cystoid macular edema secondary to retinal vein occlusion (RVO) using microperimetry and spectral domain optical coherence tomography (SD-OCT).
  35. doi Inflammatory factors in major and macular branch retinal vein occlusion
    Hidetaka Noma
    Department of Ophthalmology, Yachiyo Medical Center, Tokyo Women s Medical University, 477 96 Owada Shinden, Yachiyo, Chiba, Japan
    Ophthalmologica 227:146-52. 2012
    Concentrations of inflammatory factors were measured in 40 patients with macular edema due to major branch retinal vein occlusion (BRVO) or macular BRVO who were treated by pars plana vitrectomy...
  36. doi Effect of the duration of macular edema on clinical outcomes in retinal vein occlusion treated with dexamethasone intravitreal implant
    Wei Shi Yeh
    Allergan, Inc, Irvine, California 92612 1531, USA
    Ophthalmology 119:1190-8. 2012
    ..7 mg (Ozurdex; Allergan, Inc, Irvine, CA) in patients with ME following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO).
  37. doi Ocular neovascularization associated with central and hemicentral retinal vein occlusion
    Sohan Singh Hayreh
    Department of Ophthalmology and Visual Sciences, College of Medicine, University of Iowa, Iowa City, Iowa 52242 1091, USA
    Retina 32:1553-65. 2012
    To investigate the incidence of ocular neovascularization (NV) in central and hemicentral retinal vein occlusion.
  38. doi Ultra wide-field angiographic characteristics of branch retinal and hemicentral retinal vein occlusion
    Pradeep S Prasad
    Retina Division, Jules Stein Eye Institute, David Geffen School of Medicine at University of California, Los Angeles, California 90095 7000, USA
    Ophthalmology 117:780-4. 2010
    ..To study the peripheral angiographic features of branch retinal vein occlusions (BRVO) and hemicentral retinal vein occlusions (HRVO) and explore associations with macular edema and neovascularization...
  39. doi Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion
    Danny Mitry
    Moorfields Eye Hospital NHS Foundation Trust, London
    Cochrane Database Syst Rev 1:CD009510. 2013
    Branch retinal vein occlusion (BRVO) is one of the most common occurring retinal vascular abnormalities...
  40. doi Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve-month results of a prospective, randomized study
    David L Epstein
    Department of Ophthalmology, Karolinska Institutet, St Eriks Eye Hospital, Stockholm, Sweden
    Ophthalmology 119:2587-91. 2012
    To evaluate the efficacy of intraocular injections with bevacizumab over 12 months in patients with macular edema (ME) secondary to central retinal vein occlusion (CRVO).
  41. ncbi Cardiovascular risk factors for retinal vein occlusion and arteriolar emboli: the Atherosclerosis Risk in Communities & Cardiovascular Health studies
    Tien Yin Wong
    Centre for Eye Research Australia, University of Melbourne, Melbourne, Australia
    Ophthalmology 112:540-7. 2005
    To examine the associations of retinal vein occlusion and arteriolar emboli with cardiovascular disease.
  42. doi Natural history of branch retinal vein occlusion: an evidence-based systematic review
    Sophie L Rogers
    Centre for Eye Research Australia, University of Melbourne, Vic, Australia
    Ophthalmology 117:1094-1101.e5. 2010
    To describe the natural history of branch retinal vein occlusion (BRVO) based on the best available evidence from the literature.
  43. doi Natural history of central retinal vein occlusion: an evidence-based systematic review
    Rachel L McIntosh
    Centre for Eye Research Australia, University of Melbourne, Vic, Australia
    Ophthalmology 117:1113-1123.e15. 2010
    To describe the natural history of central retinal vein occlusion (CRVO) based on the best available evidence from the literature.
  44. doi Pegaptanib sodium for macular edema secondary to central retinal vein occlusion
    John J Wroblewski
    Cumberland Valley Retina Consultants, Hagerstown, Maryland 21740, USA
    Arch Ophthalmol 127:374-80. 2009
    To assess the safety and efficacy of intravitreous pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO).
  45. pmc The management of retinal vein occlusion: is interventional ophthalmology the way forward?
    H Shahid
    Prince Charles Eye Unit, King Edward VII Hospital, Windsor, UK
    Br J Ophthalmol 90:627-39. 2006
    ..RVOs occur at significantly high frequency to allow future prospective randomised controlled studies to be conducted to evaluate the role of different therapeutic modalities singly or in combination...
  46. doi Topography of patchy retinal whitening during acute perfused retinal vein occlusion by optical coherence tomography and adaptive optics fundus imaging
    Valerie Sarda
    Clinical Investigation Center 503, INSERM and Centre Hospitalier National d Ophtalmologie des Quinze Vingts, Universite Pierre et Marie Curie Paris 6, Paris, France
    Eur J Ophthalmol 21:653-6. 2011
    ..During perfused retinal vein occlusions, patchy retinal opacification due to acute neuronal swelling may be present. This may be difficult to document using conventional imaging techniques...
  47. doi Prospective study of a fluocinolone acetonide implant for chronic macular edema from central retinal vein occlusion: thirty-six-month results
    Nieraj Jain
    Department of Ophthalmology, Duke University, Durham, North Carolina, USA
    Ophthalmology 119:132-7. 2012
    To assess long-term visual outcomes and adverse events from a fluocinolone acetonide (FA) sustained drug delivery implant in eyes with chronic macular edema from central retinal vein occlusion (CRVO).
  48. doi Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study
    David M Brown
    Retina Consultants of Houston, The Methodist Hospital, Houston, Texas 77030, USA
    Ophthalmology 117:1124-1133.e1. 2010
    To assess the efficacy and safety of intraocular injections of 0.3 mg or 0.5 mg ranibizumab in patients with macular edema after central retinal vein occlusion (CRVO).
  49. doi Characteristics of optical coherence tomographic hyperreflective foci in retinal vein occlusion
    Ken Ogino
    Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Sakyo, Kyoto, Japan
    Retina 32:77-85. 2012
    To evaluate the hyperreflective foci in branch retinal vein occlusion and central retinal vein occlusion depicted by spectral-domain optical coherence tomography (OCT).
  50. doi Retinal vein occlusions
    Jost Jonas
    Department of Ophthalmology, Faculty of Clinical Medicine Mannheim, University of Heidelberg, Mannheim, Germany
    Dev Ophthalmol 47:111-35. 2010
    ..the area, demonstrated as leaking by FA, remains the 'reference treatment for macular edema due to branch retinal vein occlusion', according to the recent results of the SCORE Trial...
  51. doi Microperimetric changes after intravitreal triamcinolone acetonide injection for macular edema due to central retinal vein occlusion
    Fevzi Senturk
    The Istanbul Retina Institute, Istanbul, Turkey
    Retina 30:1254-61. 2010
    The purpose of this study was to evaluate the effect of intravitreal triamcinolone acetonide on macular function in cases of macular edema because of central retinal vein occlusion.
  52. doi Effect of triamcinolone acetonide on vascular endothelial growth factor and occludin levels in branch retinal vein occlusion
    Ian L McAllister
    Lions Eye Institute, Centre for Ophthalmology and Visual Science, The University of Western Australia, Perth, Australia
    Am J Ophthalmol 147:838-46, 846.e1-2. 2009
    To investigate the molecular mechanism by which triamcinolone acetonide (TA) may reduce edema in a porcine model of branch retinal vein occlusion (BRVO).
  53. doi Red blood cell phosphatidylserine exposure is responsible for increased erythrocyte adhesion to endothelium in central retinal vein occlusion
    M P Wautier
    INSERM, UMRS665, Paris, France
    J Thromb Haemost 9:1049-55. 2011
    b>Retinal vein occlusion (RVO) is a common cause of permanent loss of vision. The pathophysiology is uncertain, although enhanced erythrocyte aggregation and blood hyperviscosity have been observed...
  54. doi Serous retinal detachment associated with retinal vein occlusion
    Akitaka Tsujikawa
    Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Sakyo ku, Kyoto, Japan
    Am J Ophthalmol 149:291-301.e5. 2010
    To study the pathomorphology of serous retinal detachment (RD) associated with retinal vein occlusion by optical coherence tomography (OCT).
  55. doi Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion
    Richard F Spaide
    Vitreous Retina Macula Consultants of New York and the LuEsther T Mertz Retinal Research Center, Manhattan Eye, Ear, and Throat Hospital, New York, New York, USA
    Am J Ophthalmol 147:298-306. 2009
    To evaluate intravitreal injection of ranibizumab as a potential treatment for decreased visual acuity (VA) secondary to central retinal vein occlusion (CRVO).
  56. doi Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion
    Hidetaka Noma
    Department of Ophthalmology, Yachiyo Medical Center, Tokyo Women s Medical University, Chiba, Japan
    Ophthalmology 116:87-93. 2009
    To investigate whether interleukin (IL)-6 or vascular endothelial growth factor (VEGF) influences macular edema in patients with central retinal vein occlusion (CRVO).
  57. ncbi Photoreceptor status after resolved macular edema in branch retinal vein occlusion treated with tissue plasminogen activator
    Tomoaki Murakami
    Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Sakyo ku, Kyoto 606 8507, Japan
    Am J Ophthalmol 143:171-3. 2007
    To evaluate the integrity of photoreceptors in macular edema (ME) associated with branch retinal vein occlusion after intravitreal tissue plasminogen activator.
  58. doi Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study
    Peter A Campochiaro
    The Wilmer Eye Institute, Department of Ophthalmology and Neuroscience, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9277, USA
    Ophthalmology 117:1102-1112.e1. 2010
    To assess efficacy and safety of intraocular injections of 0.3 mg or 0.5 mg ranibizumab in patients with macular edema following branch retinal vein occlusion (BRVO).
  59. doi Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham-controlled ROCC study
    Bettina Kinge
    Retinaklinikken Aleris, Fredrik Stangsgt 11 13, Oslo, Norway
    Am J Ophthalmol 150:310-4. 2010
    ..study (randomized study comparing ranibizumab to sham in patients with macular edema secondary to central Retinal vein OCClusion [CRVO]) evaluated the short-term effect of intravitreal ranibizumab injections on best-corrected visual ..
  60. ncbi Optical coherence tomography of branch retinal vein occlusion
    Richard F Spaide
    Vitreous Retina Macula Consultants of New York and the LuEsther T Mertz Retina Research Laboratory, Manhattan Eye, Ear, and Throat Hospital, New York, New York 10021, USA
    Retina 23:343-7. 2003
    To evaluate the incidence of serous retinal detachment (SRD) secondary to a branch retinal vein occlusion (BRVO) by using optical coherence tomography (OCT).
  61. doi Intravitreal plasmin without vitrectomy for macular edema secondary to branch retinal vein occlusion
    Patricia Udaondo
    Retina and Uveitis Unit, Department of Ophthalmology, Hospital La Fe de Valencia, Valencia, Spain
    Arch Ophthalmol 129:283-7. 2011
    To evaluate the effects and safety of intravitreal injections of autologous plasmin enzyme (APE), without vitrectomy, as a treatment for macular edema secondary to branch retinal vein occlusion.
  62. doi Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans
    Tim U Krohne
    Department of Ophthalmology, University of Bonn, Bonn, Germany
    Am J Ophthalmol 146:508-12. 2008
    ..To investigate intraocular concentrations and pharmacokinetics of bevacizumab after a single intravitreal injection in humans...
  63. pmc Comparison between intravitreal bevacizumab and triamcinolone for macular edema secondary to branch retinal vein occlusion
    Jin Young Kim
    Department of Ophthalmology, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, 445 Gil 1 dong, Gangdong gu, Seoul, Korea
    Korean J Ophthalmol 23:259-65. 2009
    To compare the effects of intravitreal bevacizumab to those of triamcinolone acetonide injection for the treatment of macular edema secondary to branch retinal vein occlusion.
  64. pmc SCORE Study report 1: baseline associations between central retinal thickness and visual acuity in patients with retinal vein occlusion
    Ingrid U Scott
    Department of Ophthalmology, Penn State College of Medicine, Hershey, Pennsylvania, USA
    Ophthalmology 116:504-12. 2009
    ..measured by optical coherence tomography (OCT) and best-corrected visual acuity in eyes with macular edema associated with retinal vein occlusion and to investigate other factors associated with baseline visual acuity letter score.
  65. ncbi Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion
    Shelley R Boyd
    Moorfields Eye Hospital, City Road, London EC1V 2PD, England
    Arch Ophthalmol 120:1644-50. 2002
    To establish a role for vascular endothelial growth factor (VEGF) during the onset and clinical course of neovascularization of the iris (NVI) in ischemic central retinal vein occlusion.
  66. ncbi Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion
    Melvin D Rabena
    California Retina Consultants and Research Foundation, Santa Barbara, CA 93103, USA
    Retina 27:419-25. 2007
    ..To report the authors' experience after intravitreal bevacizumab (Avastin, Genentech) injection in patients with macular edema (ME) secondary to branch retinal vein occlusive disease (BRVO)...
  67. doi In retinal vein occlusion platelet response to thrombin is increased
    Giuliana Leoncini
    Department of Experimental Medicine, Biochemistry Section, University of Genoa, Genoa, Italy
    Thromb Res 124:e48-55. 2009
    b>Retinal vein occlusion is a major cause of ocular morbidity. The precise mechanism leading to thrombosis in retinal vein occlusion has not yet been clearly elucidated...
  68. doi Comparative analysis of homocysteine concentrations in patients with retinal vein occlusion versus thrombotic and atherosclerotic disorders
    Anat Kesler
    Department of Ophthalmology, Tel Aviv Sourasky Medical Center, Israel
    Blood Coagul Fibrinolysis 19:259-62. 2008
    ..were to determine the concentrations of plasma homocysteine in a large (n = 562) cohort of patients with retinal vein occlusion (RVO) and to compare them with the values observed in other vascular thrombotic and atherosclerotic ..
  69. doi Association of inflammatory factors with macular edema in branch retinal vein occlusion
    Hidetaka Noma
    Department of Ophthalmology, Yachiyo Medical Center, Tokyo Women s Medical University, Tokyo, Japan
    JAMA Ophthalmol 131:160-5. 2013
    To evaluate the association between vitreous fluid levels of inflammatory factors and macular edema in patients with branch retinal vein occlusion (BRVO).
  70. pmc Economic considerations of macular edema therapies
    William E Smiddy
    Bascom Palmer Eye Institute, PO Box 016880, Miami, FL 33101 6880, USA
    Ophthalmology 118:1827-33. 2011
    To relate costs and treatment benefits for diabetic macular edema (DME), branch retinal vein occlusion (BRVO), and central retinal vein occlusion (CRVO).
  71. doi Peripheral areas of nonperfusion in treated central retinal vein occlusion as imaged by wide-field fluorescein angiography
    Richard F Spaide
    Vitreous Retina Macula Consultants of New York, New York, New York, USA
    Retina 31:829-37. 2011
    To develop a method of imaging the retina using wide-field fluorescein angiography and use this method to investigate the areas of perfusion abnormalities in patients treated with ranibizumab for central retinal vein occlusion.
  72. doi Intravitreal bevacizumab vs. sham treatment in acute branch retinal vein occlusion with macular edema: results at 3 months (Report 1)
    Siamak Moradian
    Ophthalmic Research Center, Labbafinejad Medical Center, Pasdaran Ave Boostan 9 St, Tehran, 16666, Iran
    Graefes Arch Clin Exp Ophthalmol 249:193-200. 2011
    ..compare the visual and anatomical (central macular thickness; CMT) outcomes of intravitreal bevacizumab (IVB) injections relative to sham treatment in eyes with acute (less than 3 months in duration) branch retinal vein occlusion (BRVO).
  73. pmc Natural history of visual outcome in central retinal vein occlusion
    Sohan Singh Hayreh
    Department of Ophthalmology and Visual Sciences, College of Medicine, University of Iowa, Iowa City, Iowa, USA
    Ophthalmology 118:119-133.e1-2. 2011
    To investigate systematically the natural history of visual outcome in central retinal vein occlusion (CRVO).
  74. doi Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator
    Peter A Campochiaro
    Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9277, USA
    Mol Ther 16:791-9. 2008
    Macular edema is a major cause of vision loss in patients with central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO)...
  75. doi Retinal vein occlusion and the risk of stroke development: a five-year follow-up study
    Jau Der Ho
    Department of Ophthalmology, Taipei Medical University Hospital, Taipei, Taiwan
    Am J Ophthalmol 147:283-290.e2. 2009
    To investigate the risk of stroke development following the occurrence of retinal vein occlusion (RVO).
  76. pmc Cardiovascular risk assessment in patients with retinal vein occlusion
    S C Martin
    Department of Clinical Biochemistry and Immunology, Heartlands Hospital, Birmingham, UK
    Br J Ophthalmol 86:774-6. 2002
    ..The risk of future CVD was determined using the Framingham algorithm and this risk estimate was used to guide decisions about preventative treatment for CVD in RVO patients...
  77. doi Management of macular edema secondary to branch retinal vein occlusion: an evidence-based update
    Ahmad A Aref
    Penn State Hershey Eye Center, 500 University Drive, HU19, Hershey, PA 17033 0850, USA
    Adv Ther 28:28-39. 2011
    ..Retinal vein occlusions are classified as either branch retinal vein occlusion (BRVO), central retinal vein occlusion (CRVO), or hemiretinal vein occlusion (HRVO) based on the specific ..
  78. doi Changes in areas of capillary nonperfusion after intravitreal injection of bevacizumab in eyes with branch retinal vein occlusion
    Takayuki Terui
    Department of Ophthalmology, Nagoya University Graduate School of Medicine, Showa Ku, Nagoya, Japan
    Retina 31:1068-74. 2011
    To study the effect of an intravitreal bevacizumab (IVB) on the retinal ischemia in eyes with a branch retinal vein occlusion.
  79. doi Retinal vein occlusion: an approach to diagnosis, systemic risk factors and management
    J W Y Yau
    Department of Medicine, University of Melbourne, St Vincent s Hospital, Melbourne, Victoria, Australia
    Intern Med J 38:904-10. 2008
    b>Retinal vein occlusion (RVO) is the second most common retinal vascular disease after diabetic retinopathy and is a common cause of visual morbidity and blindness in the elderly...
  80. ncbi The photopic negative response of the flash electroretinogram in retinal vein occlusion
    Hongling Chen
    Zhongshan Ophthalmic Center, State Key Laboratory of Ophthalmology, Sun Yat Sen University, 54 S Xianlie Road, Guangzhou, 510060, PR China
    Doc Ophthalmol 113:53-9. 2006
    ..The aim of this study was to test how the PhNR of the flash electroretinogram (ERG) is affected in human retinal vein occlusion. PhNR was elicited with red stimuli (1 cd s/m2, 5 cd s/m2, and 7 cd s/m2 with 4 ms duration) and blue ..
  81. doi Electrophysiological consequences of experimental branch retinal vein occlusion in pigs and the effect of dorzolamide
    Rasmus Ejstrup
    Department of Ophthalmology, Glostrup Hospital, University of Copenhagen, Copenhagen, Denmark
    Invest Ophthalmol Vis Sci 52:952-8. 2011
    To study the electrophysiological consequences of experimental branch retinal vein occlusion (BRVO) in pigs and the effect of dorzolamide.
  82. ncbi Low vitamin B6 and folic acid levels are associated with retinal vein occlusion independently of homocysteine levels
    Francesco Sofi
    Department of Medical and Surgical Critical Care, Thrombosis Centre, University of Florence, Azienda Ospedaliero Universitaria Careggi, Florence, Italy
    Atherosclerosis 198:223-7. 2008
    b>Retinal vein occlusion (RVO) is one of the most common retinal vascular disorders. During the last years, high levels of homocysteine (Hcy) have been demonstrated to be an independent risk factor for RVO...
  83. doi Oxygen saturation in central retinal vein occlusion
    Sveinn Hakon Hardarson
    Department of Ophthalmology, University of Iceland Landspítali University Hospital, Reykjavik, Iceland
    Am J Ophthalmol 150:871-5. 2010
    To test whether oxygen saturation is affected in retinal blood vessels in patients with central retinal vein occlusion (CRVO).
  84. doi Prevalence and systemic risk factors for retinal vein occlusion in a general Japanese population: the Hisayama study
    Miho Yasuda
    Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
    Invest Ophthalmol Vis Sci 51:3205-9. 2010
    To examine the prevalence of retinal vein occlusion (RVO) and its systemic relevant factors in a general Japanese population aged 40 years or older.
  85. doi Retinal vein occlusion and the risk of acute myocardial infarction (correction of infraction): a 3-year follow-up study
    C C Hu
    College of Medicine, Taipei Medical University, Taipei, Taiwan
    Br J Ophthalmol 93:717-20. 2009
    Using a nationwide population-based dataset, this study investigated the relationship between retinal vein occlusion (RVO) and subsequent acute myocardial infarction (AMI).
  86. doi Intravitreal injection of autologous plasmin enzyme for macular edema associated with branch retinal vein occlusion
    Toshiro Sakuma
    Department of Ophthalmology, Juntendo University, Urayasu Hospital, Chiba, Japan
    Am J Ophthalmol 150:876-82. 2010
    To investigate the effects of an intravitreal injection of autologous plasmin enzyme for macular edema associated with a branch retinal vein occlusion (BRVO).
  87. doi Oxygen saturation in branch retinal vein occlusion
    Sveinn Hakon Hardarson
    Department of Ophthalmology, University of Iceland Landspitali The National University Hospital of Iceland, Reykjavik, Iceland
    Acta Ophthalmol 90:466-70. 2012
    The aim of this study was to test whether oxygen saturation in retinal blood vessels is affected by branch retinal vein occlusion (BRVO).
  88. doi Association between integrity of foveal photoreceptor layer and visual outcome in retinal vein occlusion
    Hyun Jin Shin
    Department of Ophthalmology, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea
    Acta Ophthalmol 89:e35-40. 2011
    To investigate the correlation between integrity of foveal photoreceptor layer and initial as well as final visual acuity (VA) after successful resolution of macular oedema (ME) associated with retinal vein occlusion (RVO).
  89. ncbi Platelet activation by collagen is increased in retinal vein occlusion
    Giuliana Leoncini
    Department of Experimental Medicine, Biochemistry Section, University of Genova, Viale Benedetto XV 1, I 16132 Genova, Italy
    Thromb Haemost 97:218-27. 2007
    b>Retinal vein occlusion (RVO) is the most common retinal vascular disorder second to diabetic retinopathy. The main risk factors in patients with RVO are hypertension, diabetes, hyperlipidemia, increased blood viscosity and glaucoma...
  90. doi Vitreous inflammatory factors and serous macular detachment in branch retinal vein occlusion
    Hidetaka Noma
    Department of Ophthalmology, Yachiyo Medical Center, Tokyo Women s Medical University, Owada shinden, Yachiyo, Chiba, Japan
    Retina 32:86-91. 2012
    ..whether vascular endothelial growth factor, soluble intercellular adhesion molecule-1 (sICAM-1), and pigment epithelium-derived factor are associated with serous retinal detachment (SRD) secondary to branch retinal vein occlusion.
  91. doi Secondary ocular hypertension after intravitreal injection with 2 mg or 4 mg of triamcinolone in retinal vein occlusion
    Lan Hsin Chuang
    Department of Ophthalmology, Chang Gung Memorial Hospital, Keelung, Taiwan
    J Ocul Pharmacol Ther 26:325-8. 2010
    To evaluate secondary ocular hypertension after intravitreal injection of triamcinolone acetonide (IVTA) with 2 mg/0.05 mL or 4 mg/0.1 mL for macular edema associated with retinal vein occlusion (RVO).
  92. doi Efficacy of vitrectomy and internal limiting membrane removal for macular edema associated with branch retinal vein occlusion
    Miyuki Arai
    Department of Ophthalmology and Visual Science, Chiba University Graduate School of Medicine, Chiba, Japan
    Ophthalmologica 223:172-6. 2009
    To compare the results of vitrectomy with internal limiting membrane (ILM) peeling to that without ILM peeling for macular edema associated with branch retinal vein occlusion (BRVO).
  93. ncbi Combined central retinal artery and vein occlusion in Churg-Strauss syndrome: case report
    Steffen Hamann
    Department of Ophthalmology, Hilleroed Hospital, Hilleroed, Denmark
    Acta Ophthalmol Scand 84:703-6. 2006
    ..To describe a rare case of Churg-Strauss syndrome presenting with severe visual loss due to a combined central retinal vein and artery occlusion...
  94. ncbi Vein occlusion in Chinese subjects
    Weiwei Liu
    Ophthalmology 114:1795-6. 2007
  95. doi Treatment of macular edema due to branch retinal vein occlusion with single or multiple intravitreal injections of bevacizumab
    Tatsuya Yunoki
    Department of Ophthalmology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama, 930 0194, Japan
    Jpn J Ophthalmol 56:159-64. 2012
    We examined the predictive factors for final visual acuity (VA) with macular edema of branch retinal vein occlusion (BRVO) treated by intravitreal injection of bevacizumab (IVB) and examined the differences between patients without ..
  96. doi Response of retinal vessels and retrobulbar hemodynamics to intravitreal anti-VEGF treatment in eyes with branch retinal vein occlusion
    Stefan Sacu
    Department of Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria
    Invest Ophthalmol Vis Sci 52:3046-50. 2011
    To investigate whether intravitreal ranibizumab (0.05 mL) treatment affects retinal vessel diameters and retrobulbar blood velocities in patients with acute branch retinal vein occlusion (BRVO).
  97. ncbi Massive macular hard exudates associated with branch retinal vein occlusion
    Kyoichi Takahashi
    Department of Ophthalmology, Gunma University School of Medicine, Maebashi, Japan
    Jpn J Ophthalmol 49:527-9. 2005
    To report four cases of branch retinal vein occlusion (BRVO) with the complication of serous retinal detachment (SRD).
  98. doi Retinal vein occlusion: current treatment
    Rosangela Lattanzio
    Department of Ophthalmology, University Vita Salute, Scientific Institute San Raffaele, Milan, Italy
    Ophthalmologica 225:135-43. 2011
    b>Retinal vein occlusion (RVO) is a pathology noted for more than 150 years. Although a lot has been written on the matter, it is still a frequent condition with multifactorial etiopathogenesis with many unclear aspects...
  99. pmc Analysis of inflammation- and atherosclerosis-related gene polymorphisms in branch retinal vein occlusion
    Iris Steinbrugger
    Centre de Recherche des Cordeliers, Universite Pierre et Marie Curie, Paris, France
    Mol Vis 15:609-18. 2009
    Branch retinal vein occlusion (BRVO) is a common vision-threatening disease. Compression of the underlying retinal vein due to increased rigidity of the crossing artery has been implicated in the pathogenesis of BRVO...
  100. doi Focal macular electroretinogram in macular edema secondary to central retinal vein occlusion
    Ken Ogino
    Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan
    Invest Ophthalmol Vis Sci 52:3514-20. 2011
    To evaluate the usefulness of focal macular electroretinography (fmERG) for evaluation of macular function in eyes with central retinal vein occlusion (CRVO).
  101. doi Nine-year incidence and risk factors for retinal vein occlusion in a general Japanese population: the Hisayama Study
    Satoshi Arakawa
    Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
    Invest Ophthalmol Vis Sci 52:5905-9. 2011
    To estimate the long-term cumulative incidence and risk factors for retinal vein occlusion (RVO) in a population-based cohort study of Japanese.

Research Grants34

  1. STATISITICAL DESIGN, MONITORING &COORD. OF VISION CLINICAL TRIALS &EPIDEMIOLOGY
    Keri Hammel; Fiscal Year: 2013
    ..Inhibitor in the Treatment of Central Retinal Vein Occlusions Number: 11-EI-0264 Background: - Central retinal vein occlusion (CRVO) is a blockage of the main vein that carries blood away from the retina in the back of the eye...
  2. STATISITICAL DESIGN, MONITORING &COORD. OF VISION CLINICAL TRIALS &EPIDEMIOLOGY
    Keri Hammel; Fiscal Year: 2012
    ..Inhibitor in the Treatment of Central Retinal Vein Occlusions Number: 11-EI-0264 Background: - Central retinal vein occlusion (CRVO) is a blockage of the main vein that carries blood away from the retina in the back of the eye...
  3. Cyr61/CCN1-Induced Angiogenesis and Vasculogenesis in the Retina
    Brahim Chaqour; Fiscal Year: 2010
    ..of a variety of ocular diseases including diabetic retinopathy, age-related macular degeneration, central retinal vein occlusion, and retinopathy of permaturity...
  4. Prevention of Retinal Degeneration by Crystallins in Experimental Uveitis
    Narsing A Rao; Fiscal Year: 2011
    ..damage has been implicated in various blinding diseases, including age-related macular degeneration, retinal vein occlusion, and glaucoma...
  5. Ocular RTEF-1 Isoforms and Control of VEGF Expression: Implications for Therapy
    John T Stout; Fiscal Year: 2013
    ..of specific isoforms are elevated under the same conditions within the retina of animal model of OIR and retinal vein occlusion (RVO)...
  6. Epidemiology of Age-related Macular Degeneration and Other Retinal Diseases
    Ronald Klein; Fiscal Year: 2012
    ..g., retinal vein occlusion;diabetic retinopathy) through cumulative 20 year incidence, regression, progression, age-period-cohort ..
  7. SCORE2 Comparative Trial (SCT)
    Ingrid U Scott; Fiscal Year: 2013
    ..trial to compare treatment protocols for decreased vision due to macular edema secondary to central retinal vein occlusion (CRVO) based on results of recent randomized trials...
  8. A Microsurgical Assistant System
    Russell H Taylor; Fiscal Year: 2012
    ..focus for our research: pathology of the retinal surface, pathology of the internal limiting membrane, and retinal vein occlusion. The specific capabilities that we propose to develop both address the specific challenges associated with ..
  9. SCORE2 Comparative Trial (SCT)
    Paul C Van Veldhuisen; Fiscal Year: 2013
    This comparative effectiveness research proposal (Studies of Comparative Treatments for REtinal Vein Occlusion 2 [SC0RE2] Study) aims to support alternative treatment protocols for decreased vision due to macular edema secondary to ..
  10. SCORE2 Comparative Trial (SCT)
    Barbara A Blodi; Fiscal Year: 2013
    The Studies of Comparative Treatments for REtinal Vein Occlusion 2 (SCORE2) is a phase III trial to study patients with central retinal vein occlusion...
  11. VISUAL FUNCTION IN RETINAL ISCHEMIA
    Mary Johnson; Fiscal Year: 1992
    A critical issue in managing patients with branch retinal vein occlusion (BVO), central retinal vein occlusion (CRVO), diabetic retinopathy or other types of ischemic retinopathy is the identification of those patients who will go on to ..
  12. CAN CD 133 CELLS PREVENT HYPOXIA DRIVEN RETINAL NEOVASCULARISATION IN A RODENT MO
    Bela Anand Apte; Fiscal Year: 2007
    ..retinopathies such as diabetic retinopathy, retinopathy of prematurity, central vein occlusion and branch retinal vein occlusion. The inhibition of vessel proliferation is the strategy utilized by current market technologies and has ..
  13. Visibly Caged Bio-active Molecules and PDT
    Paul Jones; Fiscal Year: 2004
    ..busting enzyme that could be photoactivated could form the basis of an effective treatment for Central Retinal Vein Occlusion, which currently has no treatment...
  14. Image Guidance for Active Handheld Microsurgical Tools
    Cameron Riviere; Fiscal Year: 2007
    ..Retinal vein cannulation will be used as the benchmark task. Retinal vein occlusion occurs at the rate of roughly 100,000 new cases per year, and there is currently no widely used, effective ..
  15. CENTRAL VEIN OCCLUSION STUDY, PARTICIPATING CENTER
    FRONCIE GUTMAN; Fiscal Year: 1993
    ..study will be a national collaborative randomized clinical trial of photocoagulation treatment for central retinal vein occlusion. The study will be conducted at 8-10 clinical centers with the Coordinating Center at Scott and White ..
  16. PATHOPHYSIOLOGY OF THE BLOOD-OCULAR BARRIER
    Richard Brubaker; Fiscal Year: 1999
    ..of clinical disorders including cystic fibrosis, diabetes insipidus, glaucoma, diabetes mellitus, central retinal vein occlusion, and uveitis will be made to characterize the characteristics and responsiveness of the aqueous ..
  17. STUDIES OF NORMAL AND PATHOLOGICAL RETINAL PO2
    JOHN WEITER; Fiscal Year: 1980
    ..It is hoped that long-term studies of this animal model of retinal hypoxia secondary to branch retinal vein occlusion will help elucidate the factors that contribute retinal neovascularization.
  18. Family Clustering of Incidence & Progression of Cataract
    Barbara Klein; Fiscal Year: 2003
    ..We currently have no funds to support the proposed analyses. We believe this project offers the possibility of examining important hypotheses in a large group of families in a population-based framework. ..
  19. Retinal Microvascular Characteristics/Vascular Disorders
    Ronald Klein; Fiscal Year: 2003
    ..abstract_text> ..
  20. RETINAL ARTERIOLAR ABNORMALITIES AND CV MORTALITY
    Ronald Klein; Fiscal Year: 2002
    ..Data from this study will improve the understanding of the association between microvascular characteristics and cardiovascular mortality. ..
  21. PROGRESSION OF NUCLEAR DENSITY OVER A 10-YEAR INTERVAL
    Barbara Klein; Fiscal Year: 2002
    ....
  22. WISCONSIN EPIDEMIOLOGICAL STUDY OF CARDIOVASCULAR DISEAS
    Ronald Klein; Fiscal Year: 2002
    ....
  23. Genetic Susceptibility for Development of Proliferative Diabetic Retinopathy
    Kang Zhang; Fiscal Year: 2010
    ..abstract_text> ..
  24. COLLABORATIVE INITIAL GLAUCOMA TREATMENT STUDY
    Rohit Varma; Fiscal Year: 2003
    ....
  25. Linkage Studies of Quantitative Ocular Traits
    Barbara Klein; Fiscal Year: 2006
    ..Subsequent follow-up with fine mapping of areas of interest in the genome is planned. ..
  26. Vascular Complications of Polycystic Kidney Disease
    Qi Qian; Fiscal Year: 2007
    ..This period of laboratory based study, plus the formalized career development program, is designed to train the candidate as a physician scientist with a unique expertise in vascular aspects of ADPKD. ..
  27. Microvascular - Macrovascular Disease in Type 2 Diabetes
    Ronald Klein; Fiscal Year: 2005
    ....
  28. Objective Diagnosis & Quantification of Retinal Disease
    SriniVas Sadda; Fiscal Year: 2007
    ..This technology will be of great value in future clinical and pre-clinical studies, and in everyday clinical practice. ..
  29. The Role of Polycystins in the Regulation of Intracellular Calcium and Vascular R
    Qi Qian; Fiscal Year: 2007
    ..The information gained from the proposed study will greatly enhance our understanding in the pathogenesis of vascular complications in ADPKD and provide potential areas for therapeutic targets. [unreadable] [unreadable]..
  30. Multi-Ethnic Study of Atherosclerosis-Eye Study
    Ronald Klein; Fiscal Year: 2005
    ..insights into the relative contribution of microvascular disease to the pathophysiology and natural history of subclinical and clinical cardiovascular disease, in representative populations of men and women of diverse ethnicities ..
  31. Novel Risk Factors for Chronic Kidney Disease
    Ronald Klein; Fiscal Year: 2008
    ..The new data may provide insights into the relative protective value of low levels of these markers on the incidence CKD in an aging population. [unreadable] [unreadable] [unreadable]..
  32. Novel Assessment of Early Changes in Diabetic Retinopathy
    Quan Dong Nguyen; Fiscal Year: 2010
    ..Such methods will be critically important to assessment of preventive interventions and monitoring diabetic eye disease in the future. ..
  33. Supplemental Oxygen for Hypoxia-Related Retinal Deseases
    Quan Nguyen; Fiscal Year: 2005
    ....